'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Ipca Laboratories has increased 10.33% to Rs 2308.85 crore. Operating profit margin has declined from 18.77% to 18.04%, leading to 6.03% rise in operating profit to Rs 416.42 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 25.81% to 26.14%. Purchase of finished goods cost fell from 5.62% to 5.37%. Employee cost decreased from 23.09% to 23.00%. Other expenses rose from 26.91% to 27.86%.
Other income rose 58.47% to Rs 32.66 crore. PBIDT rose 8.65% to Rs 449.08 crore. Provision for interest fell 23.04% to Rs 18.51 crore.
PBDT rose 10.61% to Rs 430.57 crore. Provision for depreciation rose 1.18% to Rs 100.06 crore.
Profit before tax grew 13.82% to ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|